Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 OBI-1 for serious bleeding in congenital hemophilia A with factor VIII inhibitors
2011-001899-18Phase 3Completed
- Sponsor
- Baxter International Inc.
- Start
- Jul 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of susoctocog alfa in hemophilia A, sponsored by Baxter International Inc. Primary endpoint: Proportion of serious bleeding episodes responsive to OBI-1 at 24 hours. Started Jul 2011; status: completed.
02
Drugs
susoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2011-001899-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001899-18.